Centrum für Hämatologie und Onkologie Bethanien

Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity (2017) Fasching P, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, et al. Journal article Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study (2017) Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Jueckstock J, Kurt A, et al. Journal article Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network (2017) Fremd C, Hack C, Schneeweiss A, Rauch G, Wallwiener D, Brucker SY, Taran FA, et al. Journal article Update Breast Cancer 2017 - Implementation of Novel Therapies (2017) Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, et al. Journal article Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R (2017) Mehilli J, Achenbach S, Woehrle J, Baquet M, Riemer T, Muenzel T, Nef HM, et al. Journal article Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study (2017) Hein A, Rack B, Li L, Ekici AB, Reis A, Lux MP, Cunningham JM, et al. Journal article Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry (2017) Wallwiener M, Heindl F, Brucker SY, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, et al. Journal article DasPAQT: Treating Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib - PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction (OMC 2014-I; BMS CA180-565) (2016) Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, et al. Conference contribution Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al. Conference contribution Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmidt W, Eidtmann H, et al. Conference contribution